TG Therapeutics CEO to participate in Cantor Global Healthcare Conference.
PorAinvest
jueves, 28 de agosto de 2025, 8:04 am ET1 min de lectura
TGTX--
Weiss will share insights into TG Therapeutics' pipeline and progress in the development of novel treatments for B-cell diseases. The company's flagship product, BRIUMVI® (ublituximab-xiiy), has received approval from various regulatory bodies for the treatment of adult patients with relapsing forms of multiple sclerosis. The company's development pipeline includes several investigational medicines, such as Ublituximab IV, TG-1701, and TG-1801 [4].
TG Therapeutics has been actively participating in the biopharmaceutical industry, with collaborations and license agreements with various partners. The company's focus on B-cell diseases highlights its commitment to addressing unmet medical needs and improving patient outcomes [4].
The Cantor Global Healthcare Conference is a significant event for the healthcare industry, bringing together leading executives, analysts, and investors to discuss the latest trends and innovations. Weiss's participation provides an opportunity for investors and industry professionals to gain insights into TG Therapeutics' strategies and future prospects [2].
References:
[1] https://www.tradingview.com/news/gurufocus:46dcfd6a7094b:0-crwv-coreweave-stock-jumps-as-cantor-sees-trillion-dollar-ai-upside/
[2] https://www.globenewswire.com/news-release/2025/08/28/3140723/8790/en/TG-Therapeutics-to-Participate-in-the-Cantor-Global-Healthcare-Conference.html
[4] https://finance.yahoo.com/quote/TGTX/
TG Therapeutics announced that CEO Michael S. Weiss will participate in the Cantor Global Healthcare Conference on September 3-5, 2025. Weiss will give a fireside chat on September 3 at 10:20am ET, and a live webcast will be available on the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases.
TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company focused on developing treatments for B-cell diseases, has announced that its CEO, Michael S. Weiss, will participate in the upcoming Cantor Global Healthcare Conference. The event will take place in New York, NY, from September 3 to 5, 2025. Weiss is scheduled to give a fireside chat on September 3 at 10:20am ET, with a live webcast available on the company's website [2].Weiss will share insights into TG Therapeutics' pipeline and progress in the development of novel treatments for B-cell diseases. The company's flagship product, BRIUMVI® (ublituximab-xiiy), has received approval from various regulatory bodies for the treatment of adult patients with relapsing forms of multiple sclerosis. The company's development pipeline includes several investigational medicines, such as Ublituximab IV, TG-1701, and TG-1801 [4].
TG Therapeutics has been actively participating in the biopharmaceutical industry, with collaborations and license agreements with various partners. The company's focus on B-cell diseases highlights its commitment to addressing unmet medical needs and improving patient outcomes [4].
The Cantor Global Healthcare Conference is a significant event for the healthcare industry, bringing together leading executives, analysts, and investors to discuss the latest trends and innovations. Weiss's participation provides an opportunity for investors and industry professionals to gain insights into TG Therapeutics' strategies and future prospects [2].
References:
[1] https://www.tradingview.com/news/gurufocus:46dcfd6a7094b:0-crwv-coreweave-stock-jumps-as-cantor-sees-trillion-dollar-ai-upside/
[2] https://www.globenewswire.com/news-release/2025/08/28/3140723/8790/en/TG-Therapeutics-to-Participate-in-the-Cantor-Global-Healthcare-Conference.html
[4] https://finance.yahoo.com/quote/TGTX/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios